يعرض 1 - 10 نتائج من 42 نتيجة بحث عن '"N-CADHERIN"', وقت الاستعلام: 0.87s تنقيح النتائج
  1. 1
    دورية أكاديمية
  2. 2
    دورية أكاديمية
  3. 3
    دورية أكاديمية
  4. 4
    دورية أكاديمية
  5. 5
    دورية أكاديمية
  6. 6
    دورية أكاديمية
  7. 7
    دورية أكاديمية
  8. 8
    دورية أكاديمية
  9. 9
    دورية أكاديمية

    المساهمون: Quintanal-Villalonga,Á, Ferrer,I, Cirauqui,C, Marrugal,Á, Ojeda,L, García,S, Zugazagoitia,J, Paz-Ares,L H12O-CNIO Lung Cancer Clinical Research Unit, Instituto de Investigacion Hospital 12 de Octubre & Centro Nacional de Investigaciones Oncológicas (CNIO), Madrid, Spain. Quintanal-Villalonga,Á Molecular Pharmacology Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA. Ferrer,I, Muñoz-Galván,S, Lopez-Rios,F, Montuenga,L, Vicent,S, Molina-Pinelo,S, Carnero,A, Paz-Ares,L CIBERONC, Madrid, Spain. Guruceaga,E Bioinformatics Unit, Centre for Applied Medical Research (CIMA), Pamplona, Spain. Guruceaga,E PROTEORED, Madrid, Spain. Zugazagoitia,J, Paz-Ares,L Medical Oncology Department, Hospital Universitario Doce de Octubre. Madrid, Spain. Muñoz-Galván,S, Carnero,A Instituto de Biomedicina de Sevilla (IBIS) (HUVR, CSIC, Universidad de Sevilla), Sevilla, Spain. Lopez-Rios,F Laboratorio de Dianas Terapeuticas, Hospital Universitario HM Sanchinarro, Madrid, Spain. Montuenga,L, Vicent,S Program in Solid Tumors, Centre for Applied Medical Research (CIMA), Pamplona, Spain. Montuenga,L, Vicent,S Department of Pathology, Anatomy and Physiology, University of Navarra, Pamplona, Spain. Montuenga,L, Vicent,S IdiSNA, Navarra Institute for Health Research, Pamplona, SPAIN. Paz-Ares,L Medical School, Universidad Complutense, Madrid, Spain., This work was funded by the Community of Madrid, the ISCIII cofunded by FEDER from Regional Development European Funds (European Union), the Spanish Ministry of Economy and Competitiveness, the Mutua Madrilena Foundation, the Ministry of Health and Social ~ Welfare of Junta de Andalucía, the AECC scientific foundation and the Spanish Ministry of Education, Culture and Sport. L.P.A. was funded by the Community of Madrid, CAM, (B2017/BMD3884), ISCIII (PIE15/00076, PI17/00778 and DTS17/00089) and CIBERONC (CD16/12/00442), and co-funded by FEDER from Regional Development European Funds (European Union). A.C. was funded by grants from the Spanish Ministry of Economy and Competitiveness Plan Estatal de I+D+I 2018 cofunded by FEDER: RTI2018-097455-B-I00, CIBER de Cancer (CB16/ 12/00275), co-funded by FEDER from Regional Development European Funds. S.M.P. is funded by the Mutua Madrilena Foundation ~ (2014) Ministry of Health and Social Welfare of Junta de Andalucía (PI-0046-2012, Nicolas Monardes Program C-0040-2016), ISCIII (PI17/00033), and co-funded by FEDER from Regional Development European Funds (European Union). I.F. is funded by the AECC scientific foundation (AIO2015) and Consejería de Igualdad, Salud y Políticas Sociales de la Junta de Andalucía (PI-0029-2013) and ISCIII (PI16/ 01311) and co-funded by FEDER from Regional Development European Funds (European Union). A.Q. is funded by ISCIII (FI12/00429). L. O. is funded by the Spanish Ministry of Education, Culture and Sport (FPU13/02595). S.V. is supported by the Spanish Ministry of Economy and Competitiveness (MINECO, SAF2017-89944-R).

    مصطلحات موضوعية: FGFR1, FGFR4, N-cadherin, Predictive biomarker, FGFR inhibitors, Fibroblast growth factor receptor 1, Fibroblast growth factor receptor 4, Biomarkers, Lung neoplasms, Cadherinas, Receptor tipo 1 de factor de crecimiento de fibroblastos, Receptor tipo 4 de factor de crecimiento de fibroblastos, Biomarcadores, Neoplasias pulmonares, Medical Subject Headings::Organisms::Eukaryota::Animals, Medical Subject Headings::Chemicals and Drugs::Chemical Actions and Uses::Pharmacologic Actions::Therapeutic Uses::Antineoplastic Agents, Medical Subject Headings::Chemicals and Drugs::Organic Chemicals::Amides::Benzamides, Medical Subject Headings::Chemicals and Drugs::Biological Factors::Biological Markers, Medical Subject Headings::Chemicals and Drugs::Amino Acids, Peptides, and Proteins::Proteins::Glycoproteins::Membrane Glycoproteins::Cell Adhesion Molecules::Cadherins, Medical Subject Headings::Diseases::Neoplasms::Neoplasms by Site::Thoracic Neoplasms::Respiratory Tract Neoplasms::Lung Neoplasms::Bronchial Neoplasms::Carcinoma, Bronchogenic::Carcinoma, Non-Small-Cell Lung, Medical Subject Headings::Anatomy::Cells::Cells, Cultured::Cell Line::Cell Line, Tumor, Medical Subject Headings::Check Tags::Female, Medical Subject Headings::Organisms::Eukaryota::Animals::Chordata::Vertebrates::Mammals::Primates::Haplorhini::Catarrhini::Hominidae::Humans, Medical Subject Headings::Diseases::Neoplasms::Neoplasms by Site::Thoracic Neoplasms::Respiratory Tract Neoplasms::Lung Neoplasms

    وصف الملف: application/pdf; application/vnd.openxmlformats-officedocument.wordprocessingml.document

    العلاقة: https://www.thelancet.com/journals/ebiom/article/PIIS2352-3964Test(20)30058-X/fulltext; Quintanal-Villalonga Á, Ferrer I, Guruceaga E, Cirauqui C, Marrugal Á, Ojeda L, et al. FGFR1 and FGFR4 oncogenicity depends on n-cadherin and their co-expression may predict FGFR-targeted therapy efficacy. EBioMedicine. 2020 Mar;53:102683; http://hdl.handle.net/10668/4460Test; PMC7047190

  10. 10
    دورية أكاديمية